Navigation Links
Mental illness and drug addiction may co-occur due to disturbance in part of the brain
Date:12/2/2007

WASHINGTON Why do mental illness and drug addiction so often go together" New research reveals that this type of dual diagnosis may stem from a common cause: developmental changes in the amygdala, a walnut-shaped part of the brain linked to fear, anxiety and other emotions. A full report on why these comorbid disorders may develop appears in the December Behavioral Neuroscience, published by the American Psychological Association (APA).

Dual diagnosis is common yet difficult to treat. Addiction of all types to nicotine, alcohol and drugs is often found in people with a wide variety of mental illnesses, including anxiety disorders, unipolar and bipolar depression, schizophrenia, and borderline and other personality disorders. Lead author Andrew Chambers, MD, cites clinical reports that at least half the people who seek help with addiction or mental-health treatment have co-occurring disorders. Epidemiological data says that from two to five of every 10 anxious or depressed people, and from four to eight of every 10 people with schizophrenia, bipolar disorder, or antisocial personality, also have some type of addiction.

To find the scientific basis for this complex, seemingly intractable pairing, which has in the past been attributed to self-medication, Chambers team at the Indiana University medical school compared the adult mood- and drug-related behavior of two groups of adult rats: those whose amygdalas were surgically damaged in infancy and those whose amygdalas were left intact but who underwent a sham surgery, to equalize their treatment.

Rats with damaged (lesioned) amygdalas grew up abnormally under-responsive to ambiguous or potentially threatening stimuli. Not showing the normal caution, they moved significantly more in response to novelty, showed significantly less fear in an elevated maze, and kept socializing even when exposed to the scent of a predator.

Crucially, these same rats also were significantly more sensitive to cocaine after just one exposure. And rats given repeated cocaine injections later showed even stronger expressions of the enduring changes in behavior suggesting an overall hypersensitivity to the addictive process.

Given that the experimental and control rats were raised in the same tightly controlled conditions, the only difference being their brain status, researchers concluded that the integrity of the amygdala was the root cause of both impaired fear behavior and heightened drug response.

Brain conditions may alter addiction vulnerability independently of drug history, says Chambers. He and his colleagues concluded that someones greater vulnerability to addiction, rather than a given drugs ability to alter the symptoms of mental illness for better or worse (usually worse), more fully explains the high rates of dual diagnosis.

For these reasons, and given the lab evidence and the fact that dual diagnosis patients do less well on psychiatric medication than other patients, Chambers wondered whether the underlying problems in the brain what he calls neural inflexibility -- make it harder for these people to respond.

To improve the effectiveness of treatments for dual diagnosis, Chambers would like to see educators, counselors, physicians, and scientific researchers integrate insights into both mental health and addiction. Funding the simultaneous treatment of both disorders would also help, he observes, given that dual-diagnosis cases are the mainstream among these patients, probably because addiction and mental illness are strongly linked by neurobiology.

What may harm the amygdala early in human development" Dr. Chambers cites the relatively rare cases of temporal lobe epilepsy, tumors or early brain injury. Far more common, he speculates, are complex interactions among subtle genetic and environmental factors that change the way the amygdala functions or is connected to the rest of the brain during childhood and adolescence. For example, he says, Early emotional trauma, paired with a certain genetic background, may alter the early development of neural networks intrinsic to the amygdala, resulting in a cascade of brain effects and functional changes that present in adulthood as a dual-diagnosis disorder.


'/>"/>

Contact: Pam Willenz
public.affairs@apa.org
202-336-5707
American Psychological Association
Source:Eurekalert

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
5. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
6. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
7. How Best to Treat Preschoolers With ADHD? The Harvard Mental Health Letter Discusses the Options
8. Experimental drug shows promise in advanced kidney cancer
9. Experimental Antidepressants Offer Faster Relief
10. Environmental stress probed in cardiovascular disease, diabetes
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation ... to further positively impact the health and wellness of our community in San ... our duty to seriously consider releasing our assets beyond our 5% targeted distribution ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — 1:30 p.m. ... critical reimbursement questions manufacturers should be asking before selecting an FDA approval ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one ... in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare ... is recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... announced today that Karen Pilley has been promoted to Chief Executive Officer. ... shifting healthcare paradigm – a shift that demands the transition from pay-for-service to ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San ... Inspirata will showcase its anatomic and molecular pathology workflow solution, as well as ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Conn. , Feb. 16, 2017 The Lockwood ... the 2017 Best Place to Work in Connecticut ... This is the third year in a row that Lockwood ... this year to earn the number-two spot in 2017. The ... maintaining workplace excellence. The winners were determined through a survey ...
Breaking Medicine Technology: